Gregory Harriman, M.D.

Gregory Harriman, M.D. has a diverse work experience in the field of life sciences and investment. Gregory currently holds the position of Partner and Chief Investment Officer at BioAdvance, a company that funds early-stage life sciences companies. Gregory has been working at BioAdvance since 2012 and has also served as a Venture Partner in the same company.

In addition to their current role, Dr. Harriman is the Director at Senzo Health, a position they have held since 2022. Gregory is also the President of Main Line Ventures since 2006.

Dr. Harriman has held various directorial positions in multiple companies. Gregory has been the Director at Opsidio, LLC since 2017, Treventis since 2012, RIBONOVA INC. from 2016 to 2021, Genome Profiling, LLC from 2017 to 2018, Immunome from 2012 to 2017, and Enzium, Inc. from 2015 to 2017.

Furthermore, Dr. Harriman has served as a Member of Robin Hood Ventures from 2010 to 2017.

Overall, Dr. Gregory Harriman has extensive experience in investment and leadership roles in the life sciences industry.

Gregory Harriman, M.D. completed their education at the University of California, Berkeley from 1974 to 1977. Although the specific degree and field of study are not mentioned, it can be inferred that they obtained a bachelor's degree during this time. Subsequently, they attended the University of California, San Diego - School of Medicine from 1977 to 1981, where they earned their medical degree (M.D.) with a specialization in Medicine.